Kornimate/medical-research-clean huggingface dataset:
positive youth development in the metaverse

Conditions: Healthy; Healthy Lifestyle; Childhood ALL; Behavior, Child

Summary: this pilot study aims to leverage vr's capacity to easily replicate content and allow for multiple users to share the same space and engage in activities as if they're meeting in person. integrating vr into afterschool programs will allow youth to receive more consistent programming content, even when they are unable to travel to the physical location for the in-person meetings.

this pilot study aims to leverage vr's capacity to easily replicate content and allow for multiple users to share the same space and engage in activities as if they're meeting in person. integrating vr into afterschool programs will allow youth to receive more consistent programming content, even when they are unable to travel to the physical location for the in-person meetings. it will also empower youth to engage with the afterschool program at their own pace by providing a safe space to learn and practice their socioemotional skills. implemented at scale, these benefits of a vr-integrated afterschool program will be able to address the issues of health inequity head on by expanding access to high quality afterschool content without incurring high operating costs. the results from this pilot study will provide a critical foundation to apply for an extramurally funded clinical trial to demonstrate the efficacy of a vr-integrated afterschool program on youth mental wellbeing. aim 1: determine feasibility of a vr-integrated afterschool program where youth can access the vr content on their own at home. aim 2: test the hypothesis that complementing the in-person afterschool program with vr will increase a) engagement and b) socioemotional competencies in youth. aim 3: test the hypothesis that youth will demonstrate better mental wellbeing when the in-person afterschool program is complemented with vr.

Eligibility criteria:
inclusion criteria: * children enrolled in the chess \& community program * between the ages of 9-17 * the parent/primary caregiver of these children exclusion criteria: * children who are unable to wear a vr headset will not be recruited

Keywords: virtual reality positive youth development afterschool program
cbt for insomnia in primary brain tumor patients

Conditions: Primary Brain Tumor; PBT

Summary: the purpose of this study is to pilot test an empirically supported psychotherapeutic intervention, cognitive behavior therapy for insomnia (cbt-i) in primary brain tumor patients. researchers hope to better understand the feasibility and acceptability of this intervention in neuro-oncology, as well as the preliminary potential benefits of this intervention on brain tumor patients' sleep, fatigue, mood, quality of life, and chronic inflammation. this may lead to improvements in treating insomnia in primary brain tumor patients.

the present study design is a pilot within-subjects pre-/post-evaluation of feasibility, acceptability, and preliminary efficacy of the cognitive behavioral therapy for insomnia (cbt-i) intervention for primary brain tumor patients. in this study, participants will be asked to do the following things: * meet with a trained interventionist six times (biweekly) for group cbt-i sessions via zoom, lasting 90 minutes each. participants will be asked to only use first names and will complete weekly sleep diaries as part of the intervention. * complete \~20-minute online surveys before the program, immediately after the program (6 weeks), and at follow-up (3 months). questions will ask about subjective sleep, fatigue, mood, and quality of life. the follow-up time point will also ask about the patient's satisfaction with the cbt-i program. * complete a brief (15 minute) cognitive evaluation before and immediately following the program. * wear a wrist-worn actigraphy monitor one week prior to the 6-week cbt-i intervention and one week following completion of the intervention. * patients currently receiving regular blood draws as part of their care at massey cancer center will have an il-6 added to their regular blood draw. those who are not receiving regular blood draws as part of their standard of care or those who are not patients at massey cancer center will forego this part of the intervention.

Eligibility criteria:
inclusion criteria: * \>/= 18 years old * confirmed primary brain tumor diagnosis * \>/= 1 month removed from radiation therapy (if applicable) * able to readily read and understand english * meeting dsm-v diagnostic criteria for insomnia as measured by the structured clinical interview for dsm-5 * sleep disorders (scisd) insomnia subsection * cognitively intact as measured by a score \>20 on the telephone interview for cognitive status (tics) * have a stable internet connection and video-capable device for zoom sessions exclusion criteria: * inability to attend weekly group in-person meetings * patients must also meet the inclusion criteria listed above.

Keywords: cognitive behavioral therapy-insomnia cbt-i
management of myofascial pain in children with sleep bruxism

Conditions: Bruxism

Summary: this study compared the effectiveness of kinesio tape and occlusal splint application in improving sleep quality and reducing myofascial pain in children with sleep bruxism.

forty-seven pediatric patients with sleep bruxism symptoms were randomly assigned into 3 groups for treatment: kinesio tape group (kt), occlusal splint group (os), and exercise group (eg). the following assessments were made in all 3 groups, before the treatment and at the end of the 1st and 5th week: wong-baker faces pain scale (wbfps), measurement of maximum mouth opening, assessment of pressure pain threshold of the bilateral masseter and temporal muscles, and evaluation of temporal and masseter muscle thickness by ultrasonography.

Eligibility criteria:
inclusion criteria: * children aged 6-11 years \[1\] presented to the clinic and had at least one symptom of sleep bruxism, * children and parents who agreed to participate in the study, * children who have not been treated for sleep bruxism before, * children who can cooperate, * children without maxillofacial trauma. exclusion criteria: * • children with psychiatric/neurological/systemic disorders, * children with a history of allergies or asthma, * children using orthodontic appliances, * children taking any medication, * children with dental abscess or fistula mouth, * children using a fixed or removable placeholder appliance.
clinical trial of coq10 for mild-to-moderate statin-associated muscle symptoms

Conditions: Pain; Weakness; Cramps; Myalgia or Myositis Nos; HMG COA Reductase Inhibitor Adverse Reaction

Summary: this study will evaluate whether a dietary supplement, coenzyme q10 (coq10), will improve muscle symptoms, such as muscle aches, pains, cramps, and/or weakness, which are experienced by some individuals who use statin medications.

this study will recruit individuals who have had muscle symptoms while using a statin. during the first part of the study, volunteers will be given a statin medication to see if their muscle symptoms return. those who experience muscle symptoms on this statin rechallenge will be invited to continue in the second part of the trial, in which participants will be randomly assigned to receive either coq10 or a placebo (sugar pill) to take with statin medication. we hypothesize that those who receive coq10 will experience an improvement in their muscle symptoms compared to those who receive placebo, and, secondarily, that those who receive coq10 will be more likely to continue taking the statin medication.

Eligibility criteria:
inclusion criteria: * patients with a history of muscle symptoms (such as aches, pains, cramps and/or weakness) while taking a statin drug that persisted for at least 2 weeks on a statin exclusion criteria: * plasma creatine kinase levels \> 3 times the upper normal limit * liver enzymes, alanine transferase (alt) or aspartate transferase (ast) \> 2 times the upper normal limit * pregnancy or breastfeeding (a contraindication for statin use) * severe renal impairment, defined as glomerular filtration rate (gfr) \< 30 ml/min/1.73 m2 * bleeding disorder, current use of warfarin, an international normalized ratio (inr) greater than 1.5, or a platelet count less than 100,000 mm3 * contraindication to strength testing, including myocardial infarction, unstable angina, or revascularization procedure within the past six weeks, a history of brain aneurysm or stroke * chest or abdominal surgery within the past six weeks * severe persistent pain related to other causes * unable to complete self-administered questionnaires, or unable to read or converse in english

Keywords: coq10 statins myalgia muscle pain muscle weakness
study to assess the effect of formoterol and beclomethasone dipropionate in asthmatic patients

Conditions: Asthma

Summary: the objective of this study is to evaluate the effect of the combination of formoterol and beclometasone dipropionate on central and peripheral airway dimensions in asthmatic patients using computational fluid dynamics (cfd). further more, the effect of this combination therapy on exhaled no, lung function (spirometry, body plethysmography, diffusion and resistance) and subjective asthma control score as well as the safety of this combination will be assessed.


Eligibility criteria:
inclusion criteria: * patients with asthma as defined by the current global initiative for asthma (gina) guidelines: * male or female patients aged ≥18 years * patients with a documented positive response to the reversibility test within the 12 months preceding the screening visit or performed at screening visit after a wash-out of 2 days for long acting β2 agonists or a documented positive response to the methacholine challenge test * patients with a co-operative attitude and ability to be trained to correctly use the pressurized metered dose inhaler (pmdi) * written informed consent obtained exclusion criteria: * pregnant or lactating females or females at risk of pregnancy * inability to carry out pulmonary function testing * diagnosis of chronic obstructive pulmonary disease (copd) as defined by the current global initiative for chronic obstructive lung disease (gold) guidelines * history of near fatal asthma * hospitalization due to asthma or symptomatic infection of the airways in the previous 8 weeks * current smokers or recent (less than one year) ex-smokers, defined as smoking at least 10 cigarettes/day * patients with an uncontrolled disease or any condition that might, in the judgement of the investigator, place the patient at undue risk or potentially compromise the results or interpretation of the study * patients with a qtc interval (bazett's formula) at the screening visit electrocardiogram (ecg) test \>450 msec * cancer or any other chronic disease with poor prognosis and /or affecting patient status * history of alcohol or drug abuse * allergy, sensitivity or intolerance to study drugs and/or study drug formulation ingredients * patients unlikely to comply with the protocol or unable to understand the nature, scope and possible consequences of the study * patients who received any investigational new drug within the last 8 weeks prior to the screening visit * patients treated with any non-permitted concomitant medication

Keywords: asthma formoterol beclomethasone dipropionate computational fluid dynamics functional imaging central and peripheral airways
corticosteroids in the treatment of tuberculous pleurisy

Conditions: Tuberculous Pleurisy

Summary: tuberculous pleurisy is associated with inflammation and fibrosis. adjunctive corticosteroids are used for tuberculous pleurisy because their anti-inflammatory effect is thought to minimise pleural reactivity and thereby reduce residual pleural thickening. the purpose is to evaluate the efficacy and safety of oral prednisolone for treatment of adult patients with tuberculous pleurisy.


Eligibility criteria:
inclusion criteria: * signed written informed consent; * presented with clinical features suggesting pleural tuberculosis; * had not previously received treatment or prophylaxis for tuberculosis; * had not recently received treatment with glucocorticoids; * were not pregnant or breast-feeding. exclusion criteria: * failed to complete the screening procedures; * were seropositive for hiv * tuberculous meningitis; * had risk factors for serious steroid-related adverse events (a history of diabetes or positive urine glucose, a history or clinical finding of hypertension, or a history of peptic ulcer disease or mental illness); * standard doses of antituberculosis drugs could not be used (as in participants with concurrent liver disease) * psychiatric illness; * alcoholism.

Keywords: tuberculosis; pleural effusion; corticosteroids.
a study of intravenous mircera (c.e.r.a or methoxy polyethylene glycol-epoetin beta) for the maintenance treatment of hemodialysis participants with chronic renal anemia

Conditions: Anemia

Summary: this 2 arm study will compare the efficacy and safety of monthly administration of intravenous (iv) mircera versus epoetin alfa for the maintenance of hemoglobin levels in hemodialysis patients with chronic renal anemia. participants currently receiving maintenance treatment with epoetin alfa will be randomized either to receive monthly injections of 120, 200 or 360 micrograms mircera, with the starting dose derived from the dose of epoetin alfa they were receiving in the week preceding study start, or to continue on epoetin alfa treatment. the anticipated duration of study is 32 weeks, and the target sample size is 146 participants.


Eligibility criteria:
inclusion criteria: * chronic renal anemia; * continuous iv maintenance epoetin alfa therapy, with the same dosing interval during the previous month to and during svp; * regular hemodialysis for greater than or equal to (\>=) 3 months exclusion criteria: * transfusion of red blood cells during previous 2 months * poorly controlled hypertension requiring interruption of epoetin alfa treatment in previous 6 months;
lipitor korean atorvastatin goal achievement across risk levels study

Conditions: Dyslipidemias

Summary: to evaluate the percentage of korean dyslipidemic subjects in the total group and each cardiovascular risk group achieving ldl-c target as defined by ncep atp ⅲ criteria at starting doses of 10mg, 20mg and 40mg of atorvastatin after 8 weeks of treatment.


Eligibility criteria:
inclusion criteria: 1. is a korean , dyslipidemic outpatient 2. is eligible for ldl-lowering drug therapy at screening and baseline as determined by the following ldl-cholesterol (ldl-c) cut-off points defined by ncep atp ⅲ: 2. 1 ldl-c ≥ 190 mg/dl for subjects with 0 or 1 chd risk factor 2. 2 ldl-c ≥ 160 mg/dl for subjects with 2 or more chd risk factors and 10 year risk \ 20 %) 3. has ldl-c ≤ 220mg/dl at baseline 4. has triglyceride level ≤ 600mg/dl at baseline exclusion criteria: 1. is pregnant or lactating 2. has present myopathy or history of myopathy or has personal or familial history of hereditary muscular disorders or any history of rhabdomyolysis 3. has history of intolerance or hypersensitivity to atorvastatin or other statins 4. uncontrolled hypertension (i.e. moderate hypertension, sitting systolic bp ≥ 160mmhg and/or diastolic bp ≥ 100mmhg) 5. has hbalc \> 10% 6. has any severe disease of has had any major problem or surgical procedure within the 3 months prior to screening that is likely to jeopardize the planned termination of the study. (e.g., any carcinoma, coronary angioplasty, coronary artery bypass graft, cardiac infarct, severe or unstable angina pectoris)
short-course radiotherapy combined with chemotherapy and pd-1 inhibitor for locally advanced colon cancer(torch-c)

Conditions: Locally Advanced Colon Cancer

Summary: the study evaluates the combination of immunotherapy of pd-1 antibody and chemotherapy and neoadjuvant short-course radiotherapy in locally advanced colon cancer (lacc). patients are randomly assigned into two prospective groups: treatment group and observerment group. in treatment group, a total of 60 patients will receive 5\*5gy short-course radiotherapy, followed by 4 cycles of capecitabine plus oxaliplatin (capox) chemotherapy and pd-1 antibody, finally receive the surgery. in observerment group: a total of 60 patients will receive 4 cycles of capox chemotherapy, then receive the surgery. the rate of pathologic complete response （pcr）, long-term prognosis and adverse effects will be analyzed.

this study is a prospective, randomized controlled, multicenter phase ii study, with a design of superior efficacy，to compare the efficacy of neoadjuvant short-course radiotherapy combined with capox chemotherapy and pd-1 immunotherapy in locally advanced colon cancer. we will consecutively enrolled patients who were diagnosed with locally advanced colon cancer with t4 stage or bulky nodes. a total of 120 patients will be randomized 1:1 to the treatment group and observerment group. in observerment group, patients will receive 4 cycles of capox (capecitabine: 1000mg/m2 d1-14 q3w; oxaliplatin: 130mg/m2 d1 q3w)chemotherapy, then receive the surgery, followed by 4 cycles of capox. in treatment group, patients will receive 5\*5gy short-course radiotherapy, followed by 4 cycles of capoxand pd-1 antibody(serplulimab,300mg d1 q3w), then receive the surgery,followed by 4 cycles of capox.

Eligibility criteria:
inclusion criteria: 1. pathological confirmed adenocarcinoma 2. clinical stage t4 and/or bulky nodes 3. the distance from anal verge more than 15 cm 4. without distance metastases 5. age \>=18 years old, female and male 6. kps \>=70 7. without previous anti-cancer therapy or immunotherapy 8. with good compliance 9. signed the inform consent exclusion criteria: 1. pregnancy or breast-feeding women 2. history of other malignancies within 5 years 3. serious medical illness, such as severe mental disorders, cardiac disease, uncontrolled infection, etc. 4. immunodeficiency disease or long-term using of immunosuppressive agents 5. baseline blood and biochemical indicators do not meet the following criteria: neutrophils≥1.5×10\^9/l, hb≥90g/l, plt≥100×10\^9/l, alt/ast ≤2.5 uln, cr≤ 1 uln 6. allergic to any component of the therapy
pressure ulcer-associated osteomyelitis: evaluation of a two-stage surgical strategy with prolonged antimicrobial therapy

Conditions: Bone Diseases, Infectious

Summary: pressure ulcer represents a frequent clinical condition in patient with spinal cord injury or after prolonged intensive care unit (icu) stay. osteomyelitis constitutes a severe complication with a poorly known management, and is associated with a high rate of relapse, leading to a high-burden in hospital bed-days, financial cost, surgical intervention, antibiotic use, morbidity and mortality, and nursing care. in our reference center for bone and joint infection management, the medical and surgical strategies are systematically discussed during pluridisciplinary meetings. most patients benefit from a two-stage surgical strategy (debridement with initiation of vacuum-assisted closure therapy until reconstruction using muscular flap) with prolonged antimicrobial therapy. in this context, our study aims to evaluate this complex approach and to determine risk factors of treatment failure in order to improve patient management, focusing on optimization of empirical antimicrobial therapy after each surgical stage, delay between the two surgical stage, and duration of antimicrobial therapy.


Eligibility criteria:
inclusion criteria: * adult patients (i.e age ≥ 18 year-old) with a osteomyelitis complication following a pressure ulcer who benefited from a two-stage surgical strategy exclusion criteria: -

Keywords: antimicrobial therapy debridement osteomyelitis muscular flap pressure ulcer treatment failure vacuum-assisted closure therapy
piperacillin/tazobactam for bacteremia with organisms producing chromosomally-encoded ampc beta-lactamase

Conditions: Bacteremia; AmpC Beta-lactamase

Summary: nosocomial bloodstream infections are important causes of morbidity and mortality caused by ampc beta-lactamase-producing enterobacteriaceae. the information collected will optimize the management of patients with nosocomial bloodstream infections.

the following information will be collected: age, sex, occupation, hospital location at the time of positive culture (er, medical ward, icu etc), prior hospitalization, receipt of outpatient dialysis, home care or other regular medical care (eg, outpatient chemotherapy), presence of invasive devices, receipt of antibiotics, including their type and whether they were adequate for the resistance profile of the organism, prior positive microbiologic cultures, time and location of positive cultures, underlying diseases and severity of illness, presence of urinary or intravascular devices, recent immunomodulative therapies or radiation therapy, physical exam findings, laboratory and radiographical data, antimicrobial usage within 30 days of onset of the infection, microbiological data and resistance patterns, choice of antibiotics once organism identified, bacteriological outcomes, laboratory results, demographic information, medications, clinical outcome,gender, height, weight, ethnicity, and past medical history. we will collect information retrospectively.

Eligibility criteria:
inclusion criteria: * clinical information is collected by chart review of "case" and "control" patients. a "case" patient is defined as follows: * one or more blood cultures are positive for e. cloacae, e. aerogenes, c. freundii, s. marcescens or m. morganii. * the patient received piperacillin/tazobactam as the initial empiric therapy. * the organism was susceptible to piperacillin/tazobactam. * a "control" patient is defined as follows: * one or more blood cultures are positive for e. cloacae, e. aerogenes, c. freundii, s. marcescens or m. morganii. * the patient received a carbapenem or fluoroquinolone antimicrobial as the initial empiric therapy. * the organism was susceptible to the empiric regimen.

Keywords: ampc beta-lactamase bacteremia piperacillin tazobactam